Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 35Breast Neoplasms 34Lung Neoplasms 20Triple Negative Breast Neoplasms 6Neoplasm Metastasis 5Adenocarcinoma of Lung 5Uterine Cervical Neoplasms 4Rhabdomyosarcoma 3Neoplasms 3NSCLC 3Hodgkin Disease 3Rhabdomyosarcoma, Embryonal 2Rhabdomyosarcoma, Alveolar 2Recurrence 2Adenocarcinoma 2Thoracic Neoplasms 1Sarcoma 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Non - Small Cell Lung Cancer NSCLC 1Neuralgia 1Metastatic HER2-positive Breast Cancer 1Mesothelioma, Malignant 1Malignant mesenchymal tumor 1Lymphoma, Non-Hodgkin 1Lymphoma 1Lung Diseases 1HR+HER2- Breast Cancer 1HER2-positive Advanced Breast Cancer 1

Interventions

figitumumab 2vandetanib 1cemiplimab 1brigatinib 1alpha-2'-deoxythioguanosine 1Vinorelbine 1Paclitaxel 1Gemcitabine 1Erlotinib Hydrochloride 1Docetaxel 1Crizotinib 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma, Large Cell × Vinorelbine × Clear all
NCT06908304 2026-01-12

A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC

Maia Biotechnology

Phase 3 Recruiting
300 enrolled
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Large Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡